{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:16:36Z","timestamp":1789690596677,"version":"4.0.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol"],"published-print":{"date-parts":[[2011,7,1]]},"DOI":"10.1001\/archdermatol.2011.54","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T01:30:55Z","timestamp":1300757455000},"page":"843","source":"Crossref","is-referenced-by-count":119,"title":["Rituximab for Patients With Refractory Mucous Membrane Pemphigoid"],"prefix":"10.1001","volume":"147","author":[{"given":"Christelle","family":"Le Roux-Villet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Prost-Squarcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Brette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Soued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Gabison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Aucouturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Letestu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"ref-dob15005-1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"issue":"8","key":"ref-dob15005-2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/archderm.135.8.954","article-title":"Mucosal morbidity in patients with epidermolysis bullosa acquisita.","volume":"135","author":"Luke","year":"1999","journal-title":"Arch Dermatol"},{"issue":"5","key":"ref-dob15005-3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00130832-200410000-00017","article-title":"Ocular cicatricial pemphigoid review.","volume":"4","author":"Foster","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"ref-dob15005-4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/01.md.0000231954.08350.52","article-title":"A prospective study of upper aerodigestive tract manifestations of mucous membrane pemphigoid.","volume":"85","author":"Alexandre","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"ref-dob15005-5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0190-9622(82)70014-3","article-title":"Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.","volume":"6","author":"Rogers","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"ref-dob15005-6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00003226-199105000-00001","article-title":"Systemic chemotherapy for ocular cicatricial pemphigoid.","volume":"10","author":"Tauber","year":"1991","journal-title":"Cornea"},{"issue":"9","key":"ref-dob15005-7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0161-6420(01)00657-1","article-title":"Treatment of ocular cicatricial pemphigoid with sulfasalazine.","volume":"108","author":"Doan","year":"2001","journal-title":"Ophthalmology"},{"issue":"11","key":"ref-dob15005-8","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"},{"issue":"9","key":"ref-dob15005-9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/archderm.137.9.1181","article-title":"Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy.","volume":"137","author":"Ahmed","year":"2001","journal-title":"Arch Dermatol"},{"issue":"1","key":"ref-dob15005-10","first-page":"101","article-title":"Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide.","volume":"137","author":"Musette","year":"2001","journal-title":"Arch Dermatol"},{"issue":"3","key":"ref-dob15005-11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/archderm.138.3.380","article-title":"Interventions for mucous membrane pemphigoid\/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review.","volume":"138","author":"Kirtschig","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"ref-dob15005-12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety.","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"ref-dob15005-13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"issue":"12","key":"ref-dob15005-14","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":"Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"ref-dob15005-15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody.","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"ref-dob15005-16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab.","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"issue":"7","key":"ref-dob15005-17","first-page":"1245","article-title":"B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"issue":"3","key":"ref-dob15005-18","first-page":"269","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.","volume":"137","author":"Borradori","year":"2001","journal-title":"Arch Dermatol"},{"issue":"1","key":"ref-dob15005-19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"issue":"4","key":"ref-dob15005-20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ced.2006.31.issue-4","article-title":"Rituximab in refractory autoimmune bullous diseases.","volume":"31","author":"Schmidt","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"ref-dob15005-21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus.","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"ref-dob15005-22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/archderm.142.2.147","article-title":"Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.","volume":"142","author":"Schmidt","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"ref-dob15005-23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bjd.2007.156.issue-1","article-title":"A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita.","volume":"156","author":"Crichlow","year":"2007","journal-title":"Br J Dermatol"},{"issue":"8","key":"ref-dob15005-24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/jdv.2007.21.issue-8","article-title":"Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita.","volume":"21","author":"Mercader","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"ref-dob15005-25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1001\/archderm.143.2.192","article-title":"Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).","volume":"143","author":"Niedermeier","year":"2007","journal-title":"Arch Dermatol"},{"issue":"2","key":"ref-dob15005-26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjd.2007.157.issue-2","article-title":"Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab.","volume":"157","author":"Sadler","year":"2007","journal-title":"Br J Dermatol"},{"issue":"7","key":"ref-dob15005-27","first-page":"731","article-title":"Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.","volume":"6","author":"Taverna","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"ref-dob15005-28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000106585","article-title":"Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.","volume":"215","author":"Wallet-Faber","year":"2007","journal-title":"Dermatology"},{"issue":"11","key":"ref-dob15005-29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.annder.2009.02.007","article-title":"Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita.","volume":"136","author":"Cavailhes","year":"2009","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"ref-dob15005-30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"ref-dob15005-31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/bjo.2007.129510","article-title":"The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement.","volume":"93","author":"Ross","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"ref-dob15005-32","doi-asserted-by":"publisher","first-page":"e979","DOI":"10.1111\/ced.2009.34.issue-8","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab.","volume":"34","author":"Saha","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"ref-dob15005-33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/1523-1747.ep12876206","article-title":"Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis.","volume":"94","author":"Bernard","year":"1990","journal-title":"J Invest Dermatol"},{"issue":"6","key":"ref-dob15005-34","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1046\/j.1365-2133.1998.02262.x","article-title":"Lichen planus pemphigoides is a heterogeneous disease: a report of five cases studied by immunoelectron microscopy.","volume":"138","author":"Bouloc","year":"1998","journal-title":"Br J Dermatol"},{"issue":"1","key":"ref-dob15005-35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-2133.1998.02038.x","article-title":"Acquired junctional epidermolysis bullosa associated with IgG autoantibodies to the beta subunit of laminin-5.","volume":"138","author":"Kirtschig","year":"1998","journal-title":"Br J Dermatol"},{"issue":"6","key":"ref-dob15005-36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/1523-1747.ep12461226","article-title":"Immunoelectron microscopy in subepidermal autoimmune bullous diseases: a prospective study of IgG and C3 bound in vivo in 32 patients.","volume":"89","author":"Prost","year":"1987","journal-title":"J Invest Dermatol"},{"issue":"8","key":"ref-dob15005-37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/02713689808951264","article-title":"Immunohistopathologic testing in patients suspected of ocular cicatricial pemphigoid.","volume":"17","author":"Demers","year":"1998","journal-title":"Curr Eye Res"},{"issue":"1","key":"ref-dob15005-38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/jaut.2000.0388","article-title":"HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus.","volume":"15","author":"Loiseau","year":"2000","journal-title":"J Autoimmun"},{"issue":"6","key":"ref-dob15005-39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0190-9622(83)70210-0","article-title":"Vesiculobullous systemic lupus erythematosus. Report of two cases and a review of the literature.","volume":"9","author":"Camisa","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"ref-dob15005-40","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"4","key":"ref-dob15005-41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1046\/j.1365-2133.1998.02168.x","article-title":"Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease.","volume":"138","author":"Setterfield","year":"1998","journal-title":"Br J Dermatol"},{"issue":"3","key":"ref-dob15005-42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1046\/j.1365-2133.2001.04380.x","article-title":"Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production.","volume":"145","author":"Setterfield","year":"2001","journal-title":"Br J Dermatol"},{"key":"ref-dob15005-43","first-page":"527","article-title":"Cicatricial pemphigoid.","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"ref-dob15005-44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab.","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"issue":"5","key":"ref-dob15005-45","first-page":"700","article-title":"Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.","volume":"90","author":"Tam","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"ref-dob15005-46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders.","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"ref-dob15005-47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"ref-dob15005-48","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Archives of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/1105130\/dob15005_843_849_1636132439.8904.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T13:30:31Z","timestamp":1636119031000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/1105130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/archdermatol.2011.54","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12738956.793459361","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.12738956.14008054","asserted-by":"object"}]},"ISSN":["0003-987X"],"issn-type":[{"value":"0003-987X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}